EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Chorioretinal Atrophy after Voretigene Neparvovec Therapy in RPE65 Mutation-Associated Inherited Retinal Disease: Longitudinal Characterization in Multimodal Imaging

Sandrine H Sassen, Marlene Sassmannshausen, Josua Sassen, Markus N Preising, Johanna P Scholz, Frank G Holz, Birgit Lorenz, Philipp Herrmann

Ophthalmologica · 2025

DOI: 10.1159/000549548 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ophthalmologica, 2025. Verfasst von Sandrine H Sassen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University of Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Multimodal Imaging, Fluorescein Angiography, Mutation, Visual Acuity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The detection of chorioretinal atrophy (CRA) following voretigene neparvovec (VN) therapy for RPE65-IRD highlights the need for long-term monitoring to better understand the safety and efficacy of this gene augmentation treatment. This study aimed to longitudinally assess the development of VN-associated CRA, its presentation in multimodal retinal imaging, and potential implications on visual function in patients with RPE65-IRD.

Methods

This single-center, prospective cohort study was conducted at the University of Bonn. A total of 21 patients with confirmed RPE65-IRD underwent subretinal VN therapy. Multimodal imaging, including blue-light fundus autofluorescence (BAF), near-infrared imaging (IR), near-infrared fundus autofluorescence (IRAF), and color fundus photography (CFP), assessed atrophy development. The primary outcome measure was the incidence and size of CRA, while secondary outcomes included the relationship between CRA and changes in visual function.

Results

The study reported a 50% (16/32 eyes) incidence of CRA, with lesions primarily located in the macula (86.7%), bleb area (86.67%), injection site (80%), and periphery (80%). Lesion detection and size varied between BAF, IR, IRAF, and CFP, with the largest CRA detected in BAF imaging. Initially, the median enlargement rate of CRA was 60.50 mm2/year (131.20). Notably, eyes with CRA development had significantly better baseline low luminance visual acuity.

Discussion

This study highlights the crucial role of multimodal imaging in monitoring VN-associated CRA. Differences in lesion detection and size assessment across imaging modalities were observed, with the largest CRA extent detected in BAF imaging. Median visual function remained stable. These findings emphasize the complexity of VN therapy outcomes and the need for close surveillance using combined multimodal imaging to better understand the long-term clinical implications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multimodal ImagingFluorescein AngiographyMutationVisual AcuityGenetic TherapyTomography, Optical Coherencecis-trans-IsomerasesDNAChoroidHumansMaleFemaleProspective StudiesAdultFundus OculiFollow-Up StudiesMiddle AgedYoung AdultAdolescentChild

Stichwörter der Autor:innen

Chorioretinal atrophyInherited retinal diseaseMultimodal retinal imagingRPE65-IRDSubretinal gene augmentation therapyVoretigene neparvovec

Substanzen

cis-trans-IsomerasesDNA

Autor:innen und Institutionen

  • Department of Ophthalmology, University of Bonn, Bonn, Germany.
  • Institute or Numerical Simulation, University of Bonn, Bonn, Germany.
  • ENS Paris Saclay, CNRS, SSA, INSERM, Centre Borelli, Université Paris Saclay, Université Paris Cité, Paris, France.
  • Department of Ophthalmology, Justus-Liebig-University Giessen, Giessen, Germany.
  • Center for Rare Diseases, University of Bonn, Bonn, Germany.
  • Department of Ophthalmology, University of Bonn, Bonn, Germany, philipp.herrmann@ukbonn.de.

Zitieren

APA

Sassen, S. H., Sassmannshausen, M., Sassen, J., Preising, M. N., Scholz, J. P., Holz, F. G., Lorenz, B., & Herrmann, P. (2025). Chorioretinal Atrophy after Voretigene Neparvovec Therapy in RPE65 Mutation-Associated Inherited Retinal Disease: Longitudinal Characterization in Multimodal Imaging. Ophthalmologica. https://doi.org/10.1159/000549548

Vancouver

Sassen SH, Sassmannshausen M, Sassen J, Preising MN, Scholz JP, Holz FG, et al. Chorioretinal Atrophy after Voretigene Neparvovec Therapy in RPE65 Mutation-Associated Inherited Retinal Disease: Longitudinal Characterization in Multimodal Imaging. Ophthalmologica. 2025. doi:10.1159/000549548

BibTeX
@article{Sassen2025,
  author = {Sassen, Sandrine H and Sassmannshausen, Marlene and Sassen, Josua and Preising, Markus N and Scholz, Johanna P and Holz, Frank G and Lorenz, Birgit and Herrmann, Philipp},
  title = {Chorioretinal Atrophy after Voretigene Neparvovec Therapy in RPE65 Mutation-Associated Inherited Retinal Disease: Longitudinal Characterization in Multimodal Imaging},
  journal = {Ophthalmologica},
  year = {2025},
  doi = {10.1159/000549548}
}
Kostenlos starten →